Creutzfeldt-Jakob disease (CJD) is a spongiform encephalopathy that results in a rapidly progressive dementia and other non-specific neurological features and death usually within a year or less from onset.
On imaging, it classically manifests as T2/FLAIR hyperintensities within the basal ganglia, the thalamus, and cortex which also show diffusion restriction on DWI/ADC sequences.
Four types of Creutzfeldt-Jakob disease have been described 2,6:
- sporadic (sCJD): accounts for 85-90% of cases
- variant (vCJD): bovine-to-human transmission of bovine spongiform encephalopathy or mad cow disease (especially if in the UK between 1981-1996), subsequent human-to-human transmission (e.g. transfusion) of vCJD
- familial (fCJD): 10% of cases (these individuals carry a PRPc mutation)
- iatrogenic (iCJD): following administration of cadaveric human pituitary hormones (pre-1985), various transplants
Creutzfeldt-Jakob disease is characterised by rapidly progressive dementia, cerebral atrophy, myoclonus, and death. Patients with vCJD present mostly with sensory and psychiatric symptoms; patients with sCJD usually present with progressive cognitive impairment and cerebellar symptoms. Cerebellar symptoms may often be prominent and early in patients with iCJD secondary to cadaveric human pituitary hormones.
- characteristic results on electroencephalography (EEG)
- CSF 14-3-3 protein: positive result in patient suspected clinically of having sCJD
A definitive diagnosis requires a brain biopsy, although in many institutions the difficulty involved in sterilising equipment renders a biopsy undesirable.
CJD is thought to be mediated via (infectious) prions, a type of protein, which manifests in sheep as the disease scrapie, and in cows as bovine spongiform encephalopathy. Prions are considered infectious in the sense that they can alter the structure of neighbouring proteins.
CJD leads to spongiform degeneration of the brain, which is thought to be caused by the conversion of normal prion protein to proteinaceous infectious particles that accumulate in and around neurons and lead to cell death.
MRI findings may be bilateral or unilateral and symmetric or asymmetric, and include:
- T2: hyperintensity
- DWI/ADC: persistent restricted diffusion (considered the most sensitive sign)
Review of sequential studies also typically demonstrates rapidly progressive cerebral atrophy.
- hypometabolism on 18FDG-PET studies
Treatment and prognosis
There is currently no curative treatment and the disease is invariably fatal with a mean survival of only 7 months for most cases.
Since 2009, CJD is a notifiable disease in Australia and by law is required to be reported to the Department of Health. CJD is also notifiable in the United Kingdom, USA and Canada.
History and etymology
It was named after Hans Gerhard Creutzfeldt, a German neurologist who first described the condition in 1920, and Alfons Maria Jakob, a German neurologist who also described the condition in a separate study.
MRI imaging features overlap with many other conditions but the presentation will be different 10,11:
- 1. Grossman RI, Yousem DM. Neuroradiology, the requisites. Mosby Inc. (2003) ISBN:032300508X. Read it at Google Books - Find it at Amazon
- 2. Lee H, Hoffman C, Kingsley PB et-al. Enhanced detection of diffusion reductions in Creutzfeldt-Jakob disease at a higher B factor. AJNR Am J Neuroradiol. 2010;31 (1): 49-54. doi:10.3174/ajnr.A1756 - Pubmed citation
- 3. Kallenberg K, Schulz-schaeffer WJ, Jastrow U et-al. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. AJNR Am J Neuroradiol. 2006;27 (7): 1459-62. AJNR Am J Neuroradiol (full text) - Pubmed citation
- 4. Finkenstaedt M, Szudra A, Zerr I et-al. MR imaging of Creutzfeldt-Jakob disease. Radiology. 1996;199 (3): 793-8. Radiology (abstract) - Pubmed citation
- 5. Tschampa HJ, Kallenberg K, Kretzschmar HA et-al. Pattern of cortical changes in sporadic Creutzfeldt-Jakob disease. AJNR Am J Neuroradiol. 28 (6): 1114-8. doi:10.3174/ajnr.A0496 - Pubmed citation
- 6. Ukisu R, Kushihashi T, Tanaka E et-al. Diffusion-weighted MR imaging of early-stage Creutzfeldt-Jakob disease: typical and atypical manifestations. Radiographics. 2006;26 Suppl 1 : S191-204. doi:10.1148/rg.26si065503 - Pubmed citation
- 7. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012;79 (14): 1499-506. doi:10.1212/WNL.0b013e31826d5fc3 - Pubmed citation
- 8. Vitali P, Maccagnano E, Caverzasi E et-al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76 (20): 1711-9. doi:10.1212/WNL.0b013e31821a4439 - Free text at pubmed - Pubmed citation
- 9. Osborns Brain. Lippincott Williams & Wilkins. ISBN:1931884218. Read it at Google Books - Find it at Amazon
- 10. Tschampa HJ, Kallenberg K, Urbach H et-al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain. 2005;128 (9): 2026-33. doi:10.1093/brain/awh575 - Pubmed citation
- 11. Castillo M. Neuroradiology Companion: Methods, Guidelines, and Imaging Fundamentals. LWW. ISBN:1451111754. Read it at Google Books - Find it at Amazon